National Defense Medical Center

Guang-Huan Sun

Sun-Yran Chang

Chung-Chih Lin

Yi-Ta Tsai

Tai-Lung Cha

Hwan-Wun Liu

Yu-Chi Lin

A pharmaceutical composition comprising sorafenib and GW5074. Said combination therapy inhibits cancer cell growth via c-Raf-PP2A-DAPK signaling transduction pathway in either in vitro or in preclinical animal model for orthotopic spontaneous kidney cancer which simulates clinical symptoms. Formation of the bond between c-Raf and GW5074 leads to conformational change which consequently increases the affinity between sorafenib and c-Raf. Binding with the specific drug target facilitates serine 308 dephosphorylation of DAPK by PP2A and induces necrosis in cancer cells. Serine 308 of DAPK protein may also be used as a biomarker for drug screening. This study provides a novel pharmaceutical composition comprising sorafenib and GW5074, a protein complex target consisting of c-Raf and DAPK for drug designing, as well as biomarkers including c-Raf protein, DAPK protein and phosphorylation status of DAPK for drug screening.

Pharmaceutical compositions and methods for treating cancer and biomarkers for drug screening

Novel GP-83 protein (human epididymis-associated disintegrin and metalloprotease 7 protein) and nucleic acid molecules are disclosed. The invention provides purified GP-83 protein, fusion protein, antigenic peptides, and anti-GP-83 antibodies. The invention also provides isolated GP-83 nucleic acid molecule, recombinant vectors containing the GP-83 nucleic acid molecule, host cells containing the recombinant vector, and non-human transgenic animals in which the GP-83 nucleic acid molecule has been introduced or interrupted.

Nucleic acid molecules and polypeptides related to h-ADAM7

Growing community of inventors

Taipei, Taiwan

Guang-Huan Sun